Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

BACKGROUND: Immune checkpoint inhibitors have revolutionized the treatment paradigm of highly lethal malignancies like advanced non-small cell lung cancer (NSCLC), demonstrating long-term tumour control and extended patient survival. Unfortunately, only 25–30% of patients experience a durable benefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Botticelli, Andrea, Cerbelli, Bruna, Lionetto, Luana, Zizzari, Ilaria, Salati, Massimiliano, Pisano, Annalinda, Federica, Mazzuca, Simmaco, Maurizio, Nuti, Marianna, Marchetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080500/
https://www.ncbi.nlm.nih.gov/pubmed/30081936
http://dx.doi.org/10.1186/s12967-018-1595-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080500/
https://www.ncbi.nlm.nih.gov/pubmed/30081936
http://dx.doi.org/10.1186/s12967-018-1595-3

Ejemplares similares